Sarcomas

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 179-200

  HaDuong, Josephine H ^a   Martin, Andrew A ^b   Skapek, Stephen X ^b   Mascarenhas, Leo ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bone; Ewing's; Nonrhabdomyosarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; ETOPOSIDE; GD 2 ANTIBODY; IFOSFAMIDE; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; EWING SARCOMA; HUMAN; NONRHABDOMYOSARCOMA SOFT TISSUE SARCOMA; OSTEOSARCOMA; PATHOPHYSIOLOGY; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; TUMOR BIOPSY; BONE NEOPLASMS; CHILD; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRESCHOOL CHILD;

BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; SARCOMA;

EID: 84915748735     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.012     Document Type: Review

References (58)

1. Klein M.J., Siegal G.P. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 2006, 125(4):555-581. 10.1309/UC6K-QHLD-9LV2-KENN.
2. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009, 152:467-478. 10.1007/978-1-4419-0284-9_27.
3. Ragland B.D., Bell W.C., Lopez R.R., et al. Cytogenetics and molecular biology of osteosarcoma. Lab Invest 2002, 82(4):365-373.
4. Folpe A.L., Goldblum J.R., Rubin B.P., et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005, 29(8):1025-1033.
5. Hattinger C.M., Potschger U., Tarkkanen M., et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002, 86(11):1763-1769. 10.1038/sj.bjc.6600332.
6. Saab R., Spunt S.L., Skapek S.X. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol 2011, 94:197-234.
7. Keller C., Arenkiel B.R., Coffin C.M., et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18:2614-2626.
8. Galindo R.L., Allport J.A., Olson E.N. ADrosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci USA 2006, 103(36):13439-13444.
9. Sorensen P.H., Lynch J.C., Qualman S.J., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. JClin Oncol 2002, 20(11):2672-2679.
10. Shern J.F., Chen L., Chmielecki J., et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014, 4:216-231. 10.1158/2159-8290.CD-13-0639.
11. Chen X., Stewart E., Shelat A.A., et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013, 24(6):710-724. 10.1016/j.ccr.2013.11.002.
12. Spunt S.L., Skapek S.X., Coffin C.M. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist 2008, 13(6):668-678.
13. Ferrari A., Miceli R., Rey A., et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer 2011, 47(5):724-731. 10.1016/j.ejca.2010.11.013.
14. Pappo A.S., Rao B.N., Jenkins J.J., et al. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children's Research Hospital experience. Med Pediatr Oncol 1999, 33(2):76-82.
15. Storlazzi C.T., Mertens F., Mandahl N., et al. Anovel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer 2003, 37(2):195-200.
16. Barretina J., Taylor B.S., Banerji S., et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010, 42(8):715-721. 10.1038/ng.619.
17. Ries LAG, Smith MA, Gurney JG, et al. editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
18. Wilkins R.M., Pritchard D.J., Burgert E.O., et al. Ewing's sarcoma of bone. Experience with 140 patients. Cancer 1986, 58(11):2551-2555.
19. Burningham Z., Hashibe M., Spector L., et al. The epidemiology of sarcoma. Clin Sarcoma Res 2012, 2(1):14. 10.1186/2045-3329-2-14.
20. Hawkins D.S., Spunt S.L., Skapek S.X. Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer 2013, 60(6):1001-1008. 10.1002/pbc.24435.
21. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238.
22. Smith A.C., Squire J.A., Thorner P., et al. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol 2001, 4(6):550-558.
23. Sung L., Anderson J.R., Arndt C., et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. JPediatr 2004, 144(5):666-668. pii:S0022-3476(04)00156-8. 10.1016/j.jpeds.2004.02.026.
24. Spunt S.L., Hill D.A., Motosue A.M., et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. JClin Oncol 2002, 20(15):3225-3235.
25. Meyer W.H., Spunt S.L. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004, 30(3):269-280. 10.1016/j.ctrv.2003.11.001.
26. Miser J.S., Krailo M.D., Tarbell N.J., et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide-a Children's Cancer Group and Pediatric Oncology Group study. JClin Oncol 2004, 22(14):2873-2876. 10.1200/JCO.2004.01.041.
27. Raney R.B., Maurer H.M., Anderson J.R., et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001, 5(1):9-15.
28. Kager L., Zoubek A., Potschger U., Cooperative German-Austrian-Swiss Osteosarcoma Study Group, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. JClin Oncol 2003, 21(10):2011-2018. 10.1200/JCO.2003.08.132.
29. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. JClin Oncol 2002, 20(3):776-790.
30. Davis A.M., Bell R.S., Goodwin P.J. Prognostic factors in osteosarcoma: a critical review. JClin Oncol 1994, 12(2):423-431.
31. Whelan J.S., Jinks R.C., McTiernan A., et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 2012, 23(6):1607-1616. 10.1093/annonc/mdr491.
32. Bacci G., Longhi A., Ferrari S., et al. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006, 45(4):469-475. 10.1080/02841860500519760.
33. Missiaglia E., Williamson D., Chisholm J., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. JClin Oncol 2012, 30(14):1670-1677. 10.1200/JCO.2011.38.5591.
34. Whelan J.S. Osteosarcoma. Eur J Cancer 1997, 33(10):1611-1618. [discussion: 1618-9].
35. Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol 2014, 804:1-30. 10.1007/978-3-319-04843-7_1.
36. Jaffe N., Frei E., Traggis D., et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. NEngl J Med 1974, 291(19):994-997. 10.1056/NEJM197411072911902.
37. Winkler K., Beron G., Delling G., et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. JClin Oncol 1988, 6(2):329-337.
38. Bielack SA, Marina N, Hook J, etal. MAP plus maintenance pegylated interferon α-2b (MPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 "good response" randomization. 2013 ASCO Annual Meeting. J Clin Oncol 2013; 31(15). Abstract Number LBA10504.
39. Bacci G., Picci P., Gherlinzoni F., et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?. Chemioterapia 1986, 5(2):140-143.
40. Grimer R.J., Taminiau A.M., Cannon S.R., Surgical Subcommittee of the European Osteosarcoma Intergroup Surgical outcomes in osteosarcoma. JBone Joint Surg Br 2002, 84(3):395-400.
41. Marulanda G.A., Henderson E.R., Johnson D.A., et al. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control 2008, 15(1):13-20.
42. Ciernik I.F., Niemierko A., Harmon D.C., et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011, 117(19):4522-4530. 10.1002/cncr.26037.
43. Heiner J.P., Miraldi F., Kallick S., et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 1987, 47(20):5377-5381.
44. Nesbit M.E., Gehan E.A., Burgert E.O., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. JClin Oncol 1990, 8(10):1664-1674.
45. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. NEngl J Med 2003, 348(8):694-701. 10.1056/NEJMoa020890.
46. Womer R.B., West D.C., Krailo M.D., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. JClin Oncol 2012, 30(33):4148-4154. 10.1200/JCO.2011.41.5703.
47. Ladenstein R., Potschger U., Le Deley M.C., et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. JClin Oncol 2010, 28(20):3284-3291. 10.1200/JCO.2009.22.9864.
48. Yock T.I., Krailo M., Fryer C.J., Children's Oncology Group, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091-a report from the Children's Oncology Group. JClin Oncol 2006, 24(24):3838-3843. 10.1200/JCO.2006.05.9188.
49. Bolling T., Schuck A., Paulussen M., et al. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol 2008, 184(4):193-197. 10.1007/s00066-008-1810-x.
50. Haeusler J., Ranft A., Boelling T., et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010, 116(2):443-450. 10.1002/cncr.24740.
51. Donaldson S.S. Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer 2004, 42(5):471-476. 10.1002/pbc.10472.
52. Bacci G., Longhi A., Briccoli A., et al. The role of surgical margins in treatment of Ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65(3):766-772. 10.1016/j.ijrobp.2006.01.019.
53. Mascarenhas L, Bond MC, Femino JD, etal. Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors: a children's oncology group trial. 2011 ASCO Annual Meeting. J Clin Oncol 2011;29(15). Abstract Number 9526.
54. Olmos D., Martins A.S., Jones R.L., et al. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011, 2011:402508. 10.1155/2011/402508.
55. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. JClin Oncol 1995, 13(3):610-630.
56. Malempati S., Hawkins D.S. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012, 59(1):5-10. 10.1002/pbc.24118.
57. Rodeberg D.A., Stoner J.A., Hayes-Jordan A., et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. JClin Oncol 2009, 27(22):3705-3711.
58. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. JClin Oncol 2002, 20(17):3586-3591.